We have previously demonstrated that GSK-3β gene expression is a target of oncogenic KRas signaling in pancreatic cancer cell lines and pancreas-specific deletion of GSK-3β in KRasG12D mice reduces cearulein-induced ADM and PanIN lesion development (Zhang et al., 2011; Ding et al., 2017). The gene discussed is KRAS; the disease is pancreatic neoplasm.